Micro Emerging Active

AZN 获得欧盟批准，Imfinzi 用于早期胃癌/胃食管交界癌

新的叙述，覆盖范围有限 — 仍在形成中。

评分

0.2

动能

▲ 0.0

文章

来源

股票代码	板块	变动
III	Technology	+9.2%
AZN	Healthcare	+0.3%

情绪时间线

三月 27, 2026

AstraZeneca stock jumps 4% after surprise trial win for lung disease drug … Bullish

三月 26, 2026

Agilent Announces Expanded Approval Of PD-L1 IHC 22C3 PharmDx In Esophageal Or … Neutral

三月 25, 2026

AstraZeneca (AZN) Announces EU Approval of Imfinzi for Early Gastric/Gastroesophageal Cancers Neutral

股票代码	板块	变动
III	Technology	+9.2%
AZN	Healthcare	+0.3%

首次发现三月 25, 2026

最后更新三月 25, 2026